CN116077485A - Application of flavonoid oroxylin in preparation of medicines for treating uterine cavity adhesion - Google Patents
Application of flavonoid oroxylin in preparation of medicines for treating uterine cavity adhesion Download PDFInfo
- Publication number
- CN116077485A CN116077485A CN202211345919.5A CN202211345919A CN116077485A CN 116077485 A CN116077485 A CN 116077485A CN 202211345919 A CN202211345919 A CN 202211345919A CN 116077485 A CN116077485 A CN 116077485A
- Authority
- CN
- China
- Prior art keywords
- oroxylin
- uterine cavity
- adhesion
- cavity adhesion
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 10
- 229930003935 flavonoid Natural products 0.000 title abstract description 8
- 150000002215 flavonoids Chemical class 0.000 title abstract description 8
- 235000017173 flavonoids Nutrition 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 10
- 230000004761 fibrosis Effects 0.000 claims abstract description 10
- 210000004291 uterus Anatomy 0.000 claims abstract description 5
- 210000004696 endometrium Anatomy 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 102000003810 Interleukin-18 Human genes 0.000 claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000028685 Asherman syndrome Diseases 0.000 abstract description 20
- 201000001389 adhesions of uterus Diseases 0.000 abstract description 19
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 10
- 230000002357 endometrial effect Effects 0.000 description 10
- 238000010186 staining Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PKDXBGYCGCYBHI-UHFFFAOYSA-N 5,7-dihydroxy-6-methoxy-2-phenyl-2H-1-benzofuran-4-one Chemical compound COC1=C(C(=O)C2=CC(OC2=C1O)C3=CC=CC=C3)O PKDXBGYCGCYBHI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010067269 Uterine fibrosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000002777 Gynatresia Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000981 basic dye Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of flavonoid oroxylin in preparation of a medicine for treating uterine cavity adhesion, and belongs to the technical field of biological medicines. The invention discovers that the flavonoid compound oroxylin can relieve the inflammation and the fibrosis degree of the uterus of a mouse with intrauterine adhesion, and shows that the oroxylin can relieve the disease process of intrauterine adhesion and has the application prospect of developing medicines for treating intrauterine adhesion.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of flavonoid compound oroxylin in preparation of medicines for treating uterine cavity adhesion.
Background
Uterine cavity adhesions (Intrauterine adhesion, IUA), also known as Asherman syndrome, are partial or complete occlusions of the uterine cavity due to damaged endometrium, which are in essence endometrial fibrosis. After the endometrium is damaged, pathogens penetrating into the wound site release injury or pathogen-related molecular patterns, injured cells release chemokines, and inflammation is initiated, and if the inflammation is continuously present, endometrial fibrosis is caused.
The functional defect of the endometrium part caused by the intrauterine adhesion can lead to repeated pregnancy loss, hypomenorrhea, pelvic pain, amenorrhea and infertility, and seriously affect the reproductive health of human beings. With the increase of clinical uterine cavity operation in recent years, the incidence of uterine cavity adhesion is also increasing, and the uterine cavity adhesion becomes the second most causative factor of female secondary infertility. The current common treatment methods include hysteroscopic adhesion decomposition surgery, placement of intrauterine devices and hormone therapy, but the recurrence rate after healing is high, and the endomembrane fibrosis cannot be relieved.
Therefore, there is an urgent need to find new drugs for treating uterine cavity adhesion and realizing endometrial reconstruction, and provide new ideas and methods for clinically treating uterine cavity adhesion.
Disclosure of Invention
The invention aims to provide application of flavonoid oroxylin in preparing medicines for treating uterine cavity adhesion.
The flavonoid compound oroxylin has a chemical name of 5, 7-dihydroxyl-6-methoxy-2-phenyl-4H-1-benzofuran-4-one, and a structural formula shown as the following formula:
in one embodiment of the invention, the effect of low dose (20 mg/kg) and high dose (40 mg/kg) of oroxylin on endometrial morphology and its inflammatory levels in mice with intrauterine adhesion was determined by HE staining, ELISA and qRT-PCR experiments.
In another embodiment of the invention, the effect of low dose (20 mg/kg) and high dose (40 mg/kg) of oroxylin on the extent of endometrial fibrosis in mice with intrauterine adhesion was determined by Masson staining and an alpha-SMA immunohistochemical assay.
The invention discovers that the flavonoid compound oroxylin can improve the shape of endometrium of a mouse with intrauterine adhesion and relieve the inflammation and the fibrosis degree, which indicates that the oroxylin can relieve the process of intrauterine adhesion diseases and has application prospect for developing medicines for treating intrauterine adhesion.
Drawings
FIG. 1 shows the results of HE staining of uterine tissue (A), the results of expression of inflammatory factor gene (B) and the results of expression of inflammatory factor in serum (C) under the action of oroxylin at various concentrations in example 1.
FIG. 2 shows results of uterine Masson staining (A) and results of alpha-SMA immunohistochemistry (B) with different concentrations of oroxylin in example 2.
Detailed Description
The invention will now be described in further detail with reference to the drawings and specific examples, which should not be construed as limiting the invention. Modifications and substitutions to methods, procedures, or conditions of the present invention without departing from the spirit and nature of the invention are intended to be within the scope of the present invention. The experimental procedures and reagents not shown in the formulation of the examples were all in accordance with the conventional conditions in the art.
The experimental materials used in the following examples are as follows:
1.1 medicaments
Oroxylin (OA) with chemical name of 5, 7-dihydroxy-6-methoxy-2-phenyl-4H-1-benzofuran-4-one and chemical formula of C 16 H 12 O 5 The molecular weight is 284.263, and the product is light yellow powder with purity provided by Chinese medical university>99%. Oroxylin was suspended using sodium carboxymethylcellulose (CMC-Na) to aid dissolution and formulated into a concentration of mother liquor for in vivo experiments.
1.2 A mouse
Female BALB/c mice (6-8 weeks old) were purchased from Jiangsu Hua Xinnuo pharmaceutical technologies Co. All mice are bred in SPF-class animal houses, the temperature of the houses is 20-22 ℃, the humidity is 40-60%, and 12-hour illumination/darkness alternation is adopted to ensure the diet drinking of animals.
Press hairEarly Ming' S study (Jiang Q, li J, pan Y, wang J, yang J, shen S), et alStem Cells 2022.), an electric scraping method was used to model the intrauterine adhesion (IUA), i.e. scraping for 3 x 8s. 32 mice were randomly divided into 4 groups (n=8): control, IUA, oroxylin low dose and oroxylin high dose. Wherein the control group was only intraperitoneally injected with the same dose of solvent; after the IUA group is molded by using an electric scratching mode, injecting the solvent with the same dosage into the abdominal cavity; the oroxylin low dose group was intraperitoneally injected with 20mg/kg oroxylin daily for 2 hours after molding using an electric scratching mode; the high dose group of oroxylin was sacrificed 2h after modelling with electric scratch mode, daily intraperitoneal injection of 40mg/kg oroxylin, after 12h and 7 days respectively, serum and uterine samples were collected and tested for their inflammation and fibrosis levels.
Example 1
Oroxylin can improve the endometrial morphology of mice with intrauterine adhesion and reduce the inflammation level
Hematoxylin (hemaloxylin) -Eosin (Eosin) staining, HE staining for short, was used to observe morphological changes in endometrium. The principle is that two dyes, namely basic dye hematoxylin and acid dye eosin, are respectively used for acting on cell nucleus and cytoplasm to change the refractive index of a cell microstructure through color, so that a cell image can be clearly displayed under a light microscope.
As shown in fig. 1A, HE staining of uterine tissue found that IUA mice had incomplete endometrial structure, reduced gland numbers, and increased inflammatory cell infiltration, but after treatment with oroxylin, endometrial structure was restored to completion, gland numbers increased, and inflammatory cell infiltration decreased, as compared to the control group. Real-time fluorescent quantitative PCR analysis of uterus revealed that expression of inflammatory factors such as IL-1β, IL-18, IL-6 was significantly reduced after treatment with oroxylin (FIG. 1B). The expression of inflammatory factors such as IL-1 beta, IL-18, IL-6 in serum was also significantly reduced after oroxylin treatment, and the therapeutic effect was superior in the high dose group to the low dose group (FIG. 1C). Showing that oroxylin can improve the endometrial morphology of mice with intrauterine adhesion and reduce the inflammation level.
Example 2
Oroxylin can relieve uterine fibrosis degree of mice with uterine cavity adhesion
Masson staining is used to reflect the degree of fibrosis in the uterus by mixing two or three anionic dyes to make the collagen fibers blue and the muscle fibers red, thus observing the collagen structure of the tissue. alpha-SMA is a marker of smooth muscle cells, and is currently also known as a marker of myofibroblasts, and immunohistochemical staining of uterine tissue with alpha-SMA also reflects the degree of fibrosis in the uterus.
As shown in FIG. 2, masson staining of uterine tissue and immunohistochemical staining of α -SMA revealed that the endometrial stroma of IUA group mice was replaced by collagen (FIG. 2A), α -SMA compared to the control group + The number of myofibroblasts was significantly increased (fig. 2B), but after treatment with oroxylin, the number of collagen fibers in endometrium and α -SMA + The number of myofibroblasts was significantly reduced, and the therapeutic effect of the high dose group was superior to that of the low dose group. Showing that the oroxylin can relieve the uterine fibrosis degree of mice with uterine cavity adhesion.
Claims (6)
1. Application of oroxylin in preparing medicine for treating uterine cavity adhesion is provided.
2. The use according to claim 1, characterized in that: the oroxylin can improve the form of uterine cavity adhesion endometrium, lighten the expression of inflammatory factors IL-1 beta, IL-18 and IL-6 in uterine tissues, and reduce the expression of inflammatory factors IL-1 beta, IL-18 and IL-6 in serum.
3. The use according to claim 1, characterized in that: the oroxylin can reduce the degree of fibrosis of uterine cavity adhesion uterus.
4. A medicine for treating uterine cavity adhesion, which is characterized in that: the active ingredient is oroxylin.
5. The uterine cavity adhesion treatment drug according to claim 4, wherein: also included are pharmaceutically acceptable carriers.
6. The uterine cavity adhesion treatment drug according to claim 4, wherein: the medicine is injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211345919.5A CN116077485A (en) | 2022-10-31 | 2022-10-31 | Application of flavonoid oroxylin in preparation of medicines for treating uterine cavity adhesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211345919.5A CN116077485A (en) | 2022-10-31 | 2022-10-31 | Application of flavonoid oroxylin in preparation of medicines for treating uterine cavity adhesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116077485A true CN116077485A (en) | 2023-05-09 |
Family
ID=86199829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211345919.5A Pending CN116077485A (en) | 2022-10-31 | 2022-10-31 | Application of flavonoid oroxylin in preparation of medicines for treating uterine cavity adhesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116077485A (en) |
-
2022
- 2022-10-31 CN CN202211345919.5A patent/CN116077485A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2581912C1 (en) | Method of treating chronic endometritis and uterine cavity synechia | |
| EP1677811B1 (en) | Medicament on the basis of honey, preparation and use thereof | |
| CN116077485A (en) | Application of flavonoid oroxylin in preparation of medicines for treating uterine cavity adhesion | |
| CN115192573B (en) | Application of demethyleneberberine hydrochloride in preparation of medicines for treating pulmonary fibrosis | |
| CN106177900B (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
| CN1911260A (en) | Application of phenolic acids active components from dandelion for inhibiting gynecologic pelvic inflammatory disease | |
| CN108451949B (en) | Application of paeoniflorin metabolite I in preparation of colitis treatment drug | |
| Zong et al. | Huayu Sanjie enema liquid relieves pain in endometriosis model rats by inhibiting inflammation, peripheral sensitization, and pelvic adhesion | |
| CN102836152B (en) | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis | |
| CN112807319A (en) | Application of Quzhazhigan in treating ischemia-reperfusion injury of small intestine | |
| CN112107575A (en) | Lignan compound combined with furocoumarin compound for treating hepatic fibrosis | |
| RU2744919C1 (en) | Remedy for the treatment of endometritis in cows | |
| RU2751034C1 (en) | Method of production of a preparation for treatment of bovine endometritis | |
| CN1111422C (en) | Injection for treating piles and its preparing process | |
| CN114712379B (en) | Application of astragaloside IV in preparing medicine for preventing and treating peritoneal dialysis intestinal complications | |
| RU2803967C1 (en) | Medical use of anemozide b4 in treatment of ulcers in oral cavity | |
| CN107126538B (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method thereof | |
| CN108524593A (en) | It is a kind of to be used to treat compound suppository of hemorrhoid and preparation method thereof | |
| CN114533748B (en) | Application of pulsatilla chinensis saponin B4 in preparation of medicines for treating or preventing hysteromyoma | |
| CN112826820B (en) | NLRP3 inhibitor and application thereof | |
| CN113244368B (en) | Application of polypeptide in preparing medicine for treating endometriosis | |
| CN103372063B (en) | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease and use thereof | |
| CN101069680B (en) | Use of 2-hydroxyl-methyl benzenesulfonic acid in preparing medicine | |
| RU2071770C1 (en) | Method of uterus cervix and ovary cancer treatment | |
| CN112438984A (en) | Pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |